IRD

+ Watchlist + Portfolio

Opus Genetics, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $4.07
52-Week Range: $1.12 – $5.81
Market Cap: $342.77M
P/E (TTM): —
EPS (TTM): -1.29
Dividend Yield: —

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: -4796.52%
Return on Assets: -48.06%
Gross Margin: -291.85%
Operating Margin: -2182.78%
Profit Margin: 0.00%
Current Ratio: 12.19
Debt/Equity: —
Total Debt: $36.20M
Free Cash Flow: $-38.56M
Revenue Growth: -73.80%
Earnings Growth: —
Enterprise Value: $286.00M

IRD Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$39.85M	$19.05M	$10.99M	$14.20M
Research & Development	$14.36M	$17.65M	$26.85M	$30.81M
Selling, General & Admin	$7.27M	$11.96M	$18.21M	$21.98M
Operating Expenses	$21.62M	$29.61M	$45.07M	$52.80M
Operating Income	$18.23M	-$10.56M	-$34.07M	-$38.60M
EBITDA	$18.22M	-$8.64M	-$57.52M	-$48.07M
Pretax Income	$18.20M	-$9.97M	-$57.53M	-$49.59M
Income Tax	$315.00K	$12.00K	$0.00	$0.00
Net Income	$17.89M	-$9.99M	-$57.53M	-$49.59M
Diluted EPS	0.87	-0.46	-2.15	-0.80
Diluted Shares	20.60M	21.59M	26.72M	62.22M

IRD Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$42.63M	$50.50M	$30.32M	$45.09M
Receivables	$4.85M	$2.33M	$5.77M	$3.17M
Current Assets	$48.99M	$53.95M	$36.61M	$50.04M
Total Assets	$48.99M	$53.95M	$36.86M	$50.24M
Current Liabilities	$2.75M	$4.04M	$11.29M	$7.78M
Long-Term Debt	—	—	—	$1.13M
Total Debt	—	—	—	$1.13M
Total Liabilities	$2.75M	$4.04M	$30.14M	$34.90M
Retained Earnings	-$71.48M	-$81.47M	-$139.00M	-$188.59M
Shareholders' Equity	$46.24M	$49.91M	$6.72M	$15.35M
Working Capital	$46.23M	$49.91M	$25.32M	$42.26M

IRD Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$14.31M	-$1.11M	-$25.58M	-$35.25M
Free Cash Flow	$14.31M	-$1.11M	-$25.58M	-$35.25M
Depreciation & Amortisation	$4.00K	$6.00K	$10.00K	$53.00K
Stock-Based Compensation	$1.81M	$3.51M	$3.36M	$3.40M
Investing Cash Flow	$0.00	$0.00	$1.21M	$0.00
Financing Cash Flow	$3.79M	$8.98M	$4.19M	$50.02M
Share Repurchases	—	$0.00	-$79.00K	-$152.00K
Net Change in Cash	$18.10M	$7.87M	-$20.18M	$14.77M

IRD Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$4.37M	$2.88M	$3.08M	$3.87M	$2.16M
Research & Development	$7.95M	$6.02M	$6.41M	$10.43M	$10.58M
Selling, General & Admin	$6.35M	$5.77M	$4.98M	$4.89M	$5.94M
Operating Expenses	$14.30M	$11.79M	$11.39M	$15.32M	$16.52M
Operating Income	-$9.93M	-$8.91M	-$8.31M	-$11.45M	-$14.36M
EBITDA	-$6.81M	-$8.89M	-$17.37M	-$15.11M	-$64.87M
Pretax Income	-$8.19M	-$7.42M	-$17.45M	-$16.52M	-$65.53M
Income Tax	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income	-$8.19M	-$7.42M	-$17.45M	-$16.52M	-$65.53M
Diluted EPS	-0.24	-0.12	-0.25	—	-0.75
Diluted Shares	33.88M	63.38M	70.64M	—	86.89M

IRD Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$41.79M	$32.43M	$30.82M	$45.09M	$59.96M
Receivables	$4.75M	$4.58M	$4.28M	$3.17M	$2.71M
Current Assets	$47.93M	$38.44M	$35.91M	$50.04M	$66.60M
Total Assets	$48.17M	$38.66M	$36.12M	$50.24M	$66.79M
Current Liabilities	$24.25M	$20.19M	$29.09M	$7.78M	$9.34M
Long-Term Debt	—	$1.00M	$1.07M	$1.13M	$1.20M
Total Debt	—	$1.00M	$1.07M	$1.13M	$1.20M
Total Liabilities	$43.09M	$21.19M	$30.16M	$34.90M	$112.62M
Retained Earnings	-$147.19M	-$154.61M	-$172.07M	-$188.59M	-$254.12M
Shareholders' Equity	$5.07M	$17.47M	$5.97M	$15.35M	-$45.84M
Working Capital	$23.68M	$18.25M	$6.82M	$42.26M	$57.26M

IRD Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$8.99M	-$10.27M	-$6.16M	-$9.83M	-$12.73M
Free Cash Flow	-$8.99M	-$10.27M	-$6.16M	-$9.83M	-$12.73M
Depreciation & Amortisation	$13.00K	$14.00K	$13.00K	$13.00K	$13.00K
Stock-Based Compensation	$913.00K	$896.00K	$816.00K	$774.00K	$1.46M
Investing Cash Flow	$0.00	$0.00	$0.00	$0.00	$0.00
Financing Cash Flow	$20.46M	$906.00K	$4.54M	$24.11M	$27.59M
Share Repurchases	-$36.00K	$0.00	$0.00	-$116.00K	-$33.00K
Net Change in Cash	$11.47M	-$9.36M	-$1.61M	$14.28M	$14.87M

Market Snapshot

About

Opus Genetics is a biotechnology company focused on developing genetic medicines for inherited retinal diseases and other genetic disorders. The company utilizes its proprietary gene therapy platforms to create treatments targeting the underlying genetic causes of vision loss and blindness. Opus Genetics is advancing a pipeline of product candidates designed to restore or preserve vision in patients with rare inherited eye diseases. The company combines cutting-edge genetic engineering with clinical development expertise to bring transformative therapies to patients with limited treatment options.